A Phase 4 interventional study of Ranibizumab 0.5 mg in Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Turkey. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2013-05-30.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing ranibizumab in Macular Degeneration — 3 open to participants now, 6 under way, 4 of them phase 3. Ranibizumab · Macular Degeneration.
Among the 125 studies testing ranibizumab in Macular Degeneration, this one is the 50th largest by enrollment of the 124 interventional ones that give a count, is one of 10 that started in 2010, is one of 33 in phase 4, and was the 53rd registered.
1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →3 of the 125 studies testing ranibizumab in Macular Degeneration are open now, in 12 countries. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Austria, Czechia, Denmark and 10 more countries
Ages 50+
AO GENERIUM · Sites in Russian Federation
Ages 50+
AbbVie · Sites in United States
By country, each count listing its studies:
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 43 · Phase 3 35 · Phase 4 33
First in 2002; this study’s year is marked. 10 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 64 across the 124 interventional studies. Of the 98 that completed or were terminated, 42 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
58 of 125 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 34th largest by enrollment of the 56 interventional ones that give a count, is one of 2 that started in 2010, is one of 18 in phase 4, and was the 17th registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
3 of the studies testing ranibizumab in Macular Degeneration that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04657289Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome) | 2027-02-04 |
| NCT05562947Phase 3Hoffmann-La RocheA Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD) | 2027-06-30 |
| NCT04853251Genentech, Inc.A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS) | 2027-07-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies testing ranibizumab in Macular Degeneration, from their registry updates:
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
The purpose of the study was to compare 2 treatment regimens for patients suffering from choroidal neovascularisation secondary to age-related macular degeneration (AMD). The first treatment regimen was the approved AMD treatment of 1 injection each month for 3 months and than re-treatment of patients who have a visual loss of more than 5 letters with monthly control (Treat and Observe). The second treatment regimen was 1 injection each month for 3 months and than extending the control period if the macula is dry during the monthly control (Treat and Extend). If the "Treat and Extend" regimen is found effective and safe, the number of ranibizumab injections, the number of patient visits, the risk of adverse events due to the intravitreal injections, and policlinic occupation number could all be reduced.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. If the disease was inactive 4 weeks later, the next visit was postponed 2 weeks to 6 weeks later. If the disease was inactive during subsequent visits, the next visit was postponed an additional 2 weeks to 8 weeks later, the maximum interval between visits. If the disease became active at any visit, the patient received ranibizumab 0.5 mg ivt and the follow-up schedule started over.
Drug: Ranibizumab 0.5 mg
Patients received ranibizumab 0.5 mg intravitreally (ivt) once a month for 3 months. All subsequent visits occurred monthly. If the disease was active, the patient received ranibizumab 0.5 mg ivt. If the disease was inactive, no treatment was administered and the patient was instructed to return 1 month later.
Drug: Ranibizumab 0.5 mg
Ranibizumab was supplied as a sterile solution in sealed glass vials.
Also known as: Lucentis
Change in Best-Corrected Visual Acuity (logMAR) From Baseline to Month 12
Best corrected visual acuity (BCVA) was assessed in the study eye. BCVA measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. Each letter on the chart has a score value of 0.02 log units. Since there are 5 letters per line, the total score for a line on the logMAR chart represents a change of 0.1 log units. The formula for calculating the logMAR BCVA score is: 0.1 + logMAR value of the best line read - 0.02 x number of letters read. A lower BCVA score indicates better vision. A negative change score indicates improvement.
Time frame: Baseline to Month 12
Change in Letter Count From Baseline to Month 12
Letter count was assessed in the study eye. Measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. A higher letter count score indicates better vision. A negative change score indicates improvement.
Time frame: Baseline to Month 12
Letter Count From Baseline to Month 12
Letter count was assessed in the study eye. Measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. Results are reported in various categories of change in letter count.
Time frame: Baseline to Month 12
Number of Visits
Time frame: Baseline to Month 12
Follow-up Duration
Follow-up duration was defined as the number of days from Baseline to study discontinuation.
Time frame: Baseline to Month 12
Change in Central Retinal Thickness From Baseline to Month 12
Retinal thickness was measured using Optical Coherence Tomography (OCT).
Time frame: Baseline to Month 12
Quality of Life
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life at Visits 2, 6, 9, 12, and 15. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated poorer function.
Time frame: Visits 2, 6, 9, 12, and 15 (up to 12 months)
| Milestone | All Patients | Treat and Extend | Treat and Observe |
|---|---|---|---|
| Started | 99 | 0 | 0 |
| Completed | 93 | 0 | 0 |
| Not completed | 6 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 4 | 0 | 0 |
| Milestone | All Patients | Treat and Extend | Treat and Observe |
|---|---|---|---|
| Started | 0 | 48 | 45 |
| Completed | 0 | 38 | 39 |
| Not completed | 0 | 10 | 6 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 |
| Withdrew: Consent withdrawal | 0 | 5 | 3 |
| Withdrew: Other | 0 | 1 | 1 |
Best corrected visual acuity (BCVA) was assessed in the study eye. BCVA measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. Each letter on the chart has a score value of 0.02 log units. Since there are 5 letters per line, the total score for a line on the logMAR chart represents a change of 0.1 log units. The formula for calculating the logMAR BCVA score is: 0.1 + logMAR value of the best line read - 0.02 x number of letters read. A lower BCVA score indicates better vision. A negative change score indicates improvement.
| logMAR | Treat and Extend | Treat and Observe |
|---|---|---|
| Change in Best-Corrected Visual Acuity (logMAR) From Baseline to Month 12 | -0.18 (-0.88 to 0.76) | -0.12 (-0.88 to 1.56) |
Letter count was assessed in the study eye. Measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. A higher letter count score indicates better vision. A negative change score indicates improvement.
| Letters | Treat and Extend | Treat and Observe |
|---|---|---|
| Change in Letter Count From Baseline to Month 12 | -9 (-44 to 38) | -6 (-44 to 78) |
Letter count was assessed in the study eye. Measurements were made using the logarithm of the minimum angle of resolution (logMAR) visual acuity testing charts. Results are reported in various categories of change in letter count.
| Percentage of patients | Treat and Extend | Treat and Observe |
|---|---|---|
| < 35 letters | 7.9 | 7.7 |
| ≥ 35 letters | 92.1 | 92.3 |
| loss > 15 letters | 10.5 | 10.3 |
| loss ≤ 15 letters or gained letter | 89.5 | 89.7 |
| loss ≥ 30 letters | 2.6 | 5.1 |
| loss < 30 letters or gained letter | 97.4 | 94.9 |
| gain ≥ 0 letter | 76.3 | 61.5 |
| Loss | 23.7 | 38.5 |
| gain ≥ 15 letter | 34.2 | 23.1 |
| gain < 15 letters or loss | 65.8 | 76.9 |
| Visits | Treat and Extend | Treat and Observe |
|---|---|---|
| Number of Visits | 12.0 (10.0 to 15.0) | 15.0 (12.0 to 15.0) |
Follow-up duration was defined as the number of days from Baseline to study discontinuation.
| Days | Treat and Extend | Treat and Observe |
|---|---|---|
| Follow-up Duration | 364.5 (310.0 to 396.0) | 366.0 (320.0 to 386.0) |
Retinal thickness was measured using Optical Coherence Tomography (OCT).
| µm | Treat and Extend | Treat and Observe |
|---|---|---|
| Change in Central Retinal Thickness From Baseline to Month 12 | 88.5 (-190.0 to 584.0) | 61.0 (-470.0 to 500.0) |
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life at Visits 2, 6, 9, 12, and 15. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated poorer function.
| Units on a scale | Treat and Extend | Treat and Observe |
|---|---|---|
| Visit 2 | 70.0 (57.0 to 87.0) | 73.0 (62.0 to 89.0) |
| Visit 6 | 71.0 (65.0 to 83.0) | 69.5 (60.0 to 79.0) |
| Visit 9 | 69.0 (63.0 to 80.0) | 72.5 (62.0 to 92.0) |
| Visit 12 | 72.0 (64.0 to 84.0) | 71.0 (60.0 to 91.0) |
| Visit 15 | 69.0 (64.0 to 80.0) | 70.5 (57.0 to 85.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treat and Extend | — | 5/48 (10.4%) | 10/48 (20.8%) |
| Treat and Observe | — | 3/45 (6.7%) | 8/45 (17.8%) |
| Before Randomization | — | 2/6 (33.3%) | 1/6 (16.7%) |
| Event | Treat and Extend | Treat and Observe | Before Randomization |
|---|---|---|---|
| ArrhythmiaCardiac disorders | 0/48 | 0/45 | 1/6 |
| AzotemiaRenal and urinary disorders | 0/48 | 0/45 | 1/6 |
| Mitral valve incompetenceCardiac disorders | 0/48 | 1/45 | 0/6 |
| Aphasia SyncopePsychiatric disorders | 0/48 | 1/45 | 0/6 |
| Vascular graftSurgical and medical procedures | 1/48 | 1/45 | 0/6 |
| DiarrheaGastrointestinal disorders | 1/48 | 0/45 | 0/6 |
| Lower and upper limb fractureMusculoskeletal and connective tissue disorders | 1/48 | 0/45 | 0/6 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/48 | 0/45 | 0/6 |
| Herpes zosterSkin and subcutaneous tissue disorders | 1/48 | 0/45 | 0/6 |
| Event | Treat and Extend | Treat and Observe | Before Randomization |
|---|---|---|---|
| InfluenzaRespiratory, thoracic and mediastinal disorders | 8/48 | 5/45 | 0/6 |
| HypertensionVascular disorders | 1/48 | 2/45 | 1/6 |
| Adenoviral conjunctivitisEye disorders | 2/48 | 3/45 | 0/6 |
Safety population: All patients who received study drug (n=99). Not all patients who received study drug were randomized into the 2 treatment groups (n=93) due to discontinuation from the study in the first Period of the study. Baseline Characteristics are only reported for the randomized (n=93) patients.
| Age Continuous(years) | Treat and Extend | Treat and Observe | Total |
|---|---|---|---|
| Mean | 70.8 ± 8.8 | 71.1 ± 8.4 | 70.9 ± 8.6 |
| Sex: Female, Male(Participants) | Treat and Extend | Treat and Observe | Total |
|---|---|---|---|
| Female | 23 | 20 | 43 |
| Male | 25 | 25 | 50 |
The record gives a start of Feb 2010, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.
Results were first posted in May 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab